The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Phase I follow-up results for CYP-001, a mesenchymal stem cell product for steroid-refractory acute GvHD

Jul 30, 2020

Positive results were announced today for the phase I trial ( NCT02923375 )of CYP-001, the first commercially developed mesenchymal stem cell product available. 1The primary endpoints of this trial were the safety and efficacy of CYP-001 in adults with steroid-refractory acute graft- versus-host disease (SRaGvHD).  The secondary endpoints were complete response, partial response, and overall survival (OS) at Days 28 and 100. The initial evaluation of this multicenter, non-randomized study showed favorable results, with a CR rate of 53% and an OS of 87% at Day 100.

The follow-up results, obtained from 15 patients included in this trial, showed that the OS rate was 60% after 2 years, which compared favorably to historic controls: 1- or 2-year OS ranged from 17%−40% in previous studies. No safety concerns or serious treatment-related adverse events were recorded.

Allogeneic mesenchymoangioblast-derived mesenchymal stem cells make up the active agent of CYP-001. These cells are derived from induced pluripotent stem cells. CYP-001 will be advanced into a phase II trial for SR-GvHD, COVID-19, and critical limb ischemia, and a phase III trial for osteoarthritis.

  1. Cynata Therapeutics. Cynata completes phase 1 GvHD clinical trial follow-up with positive results. Published July 30, 2020. Accessed July 30, 2020.